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ABSTRACT
Prostate cancer (PC) risk differs between races, and we previously showed
prostate inflammation in benign prostate tissue was linked with a lower future PC
risk. However, whether prostate tissue inflammation varies by race is unknown.
We analyzed baseline acute and chronic prostate inflammation by race in REDUCE,
a 4-year, multicenter, placebo-controlled study where all men had a negative
prostate biopsy prior to enrollment. We included 7,982 men with standardized
central pathology review to determine the presence or absence of chronic or acute
inflammation in baseline prostate biopsy tissue. Logistic regression was used to
compare prostate inflammation by race, adjusting for confounders. Of 7,982 men,
7,271 were white (91.1%), 180 (2.3%) black, 131 (1.6%) Asian, 319 (4.0%) Hispanic
and 81 (1%) unknown. A total of 78% had chronic and 15% had acute inflammation.
On multivariable analysis relative to white men, black men were less likely (OR = 0.65,
95%CI: 0.41-1.03, p = 0.07) and Asian men more likely to have acute inflammation
(OR = 1.74, 95%CI: 1.14-2.65, p = 0.001). Hispanic men had similar levels of acute
inflammation as white men. Chronic inflammation did not significantly differ across
races. We identified racial differences in acute inflammation, particularly in Asian
men, in benign prostate tissue that inversely mirrored population-level data on PC
race disparity. As we showed in REDUCE that acute inflammation is linked with lower
future PC risk, if validated in future studies, these data suggest racial differences in
prostatic acute inflammation may contribute in part to race differences in PC risk,
especially among Asian men.
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INTRODUCTION

Importantly, data of prostate tissue inflammation are
limited on men of races beyond black and white.
Given prostate tissue inflammation in REDUCE is
associated with lower future PC risk, and PC incidence
and mortality rates vary by race (higher among black
men and lower among Asian men vs. whites [11]), we
determined whether prostate inflammation varied by race
by analyzing prostate inflammation patterns in negative
biopsies in REDUCE, where men were recruited globally.
We hypothesized prostate inflammation would vary by
race with black men having less inflammation (suggesting
higher PC risk) and Asian men would more inflammation
(suggesting lower PC risk) versus white men.

While it has been postulated inflammation drives
prostate cancer (PC) development [1], the link between
inflammation and PC risk appears to be complex.
Indeed some studies suggest inflammation may even be
associated with lower PC risk [2, 3]. Moreover, other data
suggest there are differences between races in the degree
of inflammatory gene expression within the tumors [4, 5].
The REDUCE study provides a unique opportunity
to evaluate the association between inflammation and
future PC risk. REDUCE was a multinational randomized
clinical trial designed to compare the effect of dutasteride
on PC diagnosis among men with a negative prestudy biopsy and elevated PSA [6]. This biopsy was
centrally reviewed by a single pathologist who graded
it systematically for inflammation. Analyzing negative
biopsies from 6,238 men in REDUCE who had a
subsequent biopsy, we previously found acute and chronic
inflammation was present, respectively, in 15% and 77%
of negative biopsies [2]. The presence of inflammation,
either acute or chronic, was linked with a 35-40% lower
PC risk on a biopsy taken 2 years later. However, on
the 4-yr biopsy only acute inflammation was associated
with reduced PC risk. Similar results were found in a
Finnish study of 293 men with a negative biopsy, with
histological inflammation associated with decreased PC
risk at follow-up [3]. Collectively these studies suggest
acute inflammation in a benign biopsy may portend
a lower future PC risk. In contrast, a study of 400 men
(84% white) in the placebo arm of the PC Prevention
Trial (PCPT) who underwent end of study biopsy, men
with PC on biopsy, especially high-grade PC, were
more likely to have inflammation (typically chronic) in
the benign cores from the same biopsy vs. men without
PC [7]. Likewise, we previously found predominantly
chronic inflammation in PC tissue correlated with worse
outcomes (recurrence after surgery) [8]. This suggests the
co-occurrence of chronic inflammation and PC correlates
with more aggressive PC. Whether these disparate results
reflect differences in acute vs. chronic inflammation or
differences in examining benign prostate tissue predicting
future PC risk vs. looking at PC tissue is not clear.
Some studies suggest there may be race differences
in inflammation. Data from NHANES from 1999-2002
found healthy black men have higher levels of circulating
inflammatory markers, such as C-reactive protein (CRP)
and fibrinogen, vs. white men [9]. Another study found
Black men had significantly higher prostate tumor
expression of IL1β, IL6, and IL8 compared to white men
[4]. One prior small (n = 238) study did find inflammation
was equally common in radical prostatectomy tissue of
white vs. black men [10]. However, that study did not
discriminate between acute and chronic inflammation,
and since all men had PC, the potential influence of the
tumor on inflammation levels could not be addressed.
www.impactjournals.com/oncotarget

RESULTS
Study subjects demographics
In our study cohort (n = 7,982), 7,271 (91%) were
white, 180 (2%) were black, 131 (2%) were Asian, 319
(4%) were Hispanic, and 81 (1%) were men of unknown
race. Race was significantly associated with geographic
region (p < 0.001), abnormal DRE (p < 0.001), PSA (p
= 0.018), prostate volume (p < 0.001), and aspirin and/
or NSAID use (p < 0.001) (Table 1). Race was also
significantly associated with the presence of acute
inflammation (p = 0.015), but not with the presence of
chronic inflammation (p = 0.112) in the pre-study negative
biopsy (Table 1).

Inflammation and race
On univariable analysis, with white race as the
reference, Asian men were more likely to have acute
inflammation (OR = 1.94, 95%CI: 1.31-2.88, p = 0.001)
(Table 2). No other races were significantly associated
with acute inflammation. After adjusting for demographic
and clinical characteristics, black race was associated with
a suggestively lower likelihood of having baseline acute
inflammation (OR = 0.65, 95%CI: 0.41-1.03, p = 0.065)
while the likelihood of having acute prostate inflammation
remained significantly higher in Asians vs. white men
(OR = 1.74, 95%CI: 1.14-2.65, p = 0.010). Hispanic
race/ethnicity remained not significantly associated
with acute inflammation on multivariable analysis.
Given the differences in results between univariable and
multivariable analyses between black men and acute
inflammation risk, we examined which factor had the
greatest influence on altering the odds ratio by adding
each variable to the multivariable model one at a time.
When this was done, we found that region and prostate
volume had the greatest effect on altering the OR between
univariable and multivariable analyses.
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Table 1: Baseline Patient Characteristics by Race (N = 7901)
No. patients (%)
Age (year), Mean (SD)
Region (%)
North America
Europe
Other
DRE (%)
Normal
Abnormal
PSA (ng/mL), M(Q1,Q3)
PV (cm3), M(Q1,Q3)
Smoking (%)
Never
Former
Current
Aspirin/NSAID use (%)
No
Yes
Acute Inflammation (%)
Chronic Inflammation (%)
No Inflammation (%)
Biopsy Results (%)
No on-study biopsies
1 negative on-study biopsy
2 negative on-study biopsies
Cancer detected on-study

Race
White
7271 (92%)
62.8 (6)

Black
180 (2%)
62.9 (6.2)

Asian
131 (2%)
62.3 (6.7)

Hispanic
319 (4%)
62.2 (6.2)

1783 (24%)
4787 (66%)
701 (10%)

135 (75%)
12 (7%)
33 (18%)

57 (44%)
7 (5%)
67 (51%)

76 (24%)
2 (1%)
241 (75%)

P-value
0.371
<0.0012

0.0012
7016 (97%)

165 (92%)

127 (97%)

299 (94%)

255 (3%)
5.7 (4.4, 7.3)
43.4 (32.9, 56.3)

15 (8%)
5.3 (4.2, 7.0)
43.7 (34.2, 62.1)

4 (3%)
5.5 (4.1, 7.3)
34.2 (26.3, 46.5)

20 (6%)
5.2 (4.1, 7.3)
47.4 (35.9, 61.5)

3323 (46%)
2860 (39%)
1088 (15%)

91 (50%)
59 (33%)
30 (17%)

49 (37%)
52 (40%)
30 (23%)

153 (48%)
123 (39%)
43 (13%)

5192 (71%)
2079 (29%)
1113 (15%)
5616 (77%)
1595 (22%)

114 (63%)
66 (37%)
24 (13%)
148 (82%)
32 (18%)

106 (81%)
25 (19%)
34 (26%)
105 (80%)
25 (19%)

269 (84%)
50 (16%)
45 (14%)
259 (81%)
57 (18%)

1202 (17%)
734 (11%)
3736 (53%)
1367 (19%)

52 (30%)
26 (15%)
62 (36%)
33 (19%)

23 (18%)
15 (12%)
76 (59%)
15 (11%)

55 (18%)
29 (9%)
171 (55%)
55 (18%)

0.0183
<0.0013
0.0762

<0.0012

0.0072
0.1332
0.1622
<0.0012

Abbreviations: DRE, digital rectal examination; PSA, prostate-specific antigen; PV, prostate volume; SD, standard deviation;
M, Median; Q1, 25th percentile; Q3, 75th percentile.
1
P-value calculated using Student ANOVA; 2 P-value calculated using Chi-squared test; 3P-value calculated using KruskalWallis test.
There were no significant associations between
prostate chronic inflammation and race in either
univariable or multivariable analysis (Table 3).

among NSAID and/or aspirin users (Supplementary Table
2), none of the interactions between race and NSAID and/
or aspirin use were significant (all p-interaction≥0.072),
suggesting the associations between race and inflammation
were statistically the same regardless of NSAID and/or
aspirin use.

Sensitivity analyses
In sensitivity analysis, we were concerned as region
and race were closely related and including regions with
limited racial diversity may affect the results. Specifically,
men enrolled in Europe were rarely black (n = 12, 0.2%)
or Asian (n = 7, 0.1%). Therefore, we repeated our
analysis excluding men from Europe and results were little
changed (Supplementary Table 1). Similarly, when not
adjusting for prostate cancer diagnosis, results were little
changed (data not shown). When stratifying analyses by
NSAID and/or aspirin use, we found acute inflammation
remained positively associated with Asian race (OR = 1.82
95%CI: 1.13-2.93, p = 0.014), and inversely associated
with black race, (OR = 0.42, 95%CI: 0.22-0.82, p = 0.012)
among non-users only. While there were no significant
associations between any race and acute inflammation
www.impactjournals.com/oncotarget

DISCUSSION
Age, race and family history are well-established PC
risk factors. PC rates in Asians are lower than in whites
and Hispanics, while black men are disproportionally
affected by PC [12]. The reasons for these disparities
are unclear. In trying to understand a mechanistic
underpinning of race disparities, we note some data
suggesting racial differences in inflammation [9, 13],
as well as data linking inflammation and PC risk, albeit
with conflicting results [2, 3, 7, 14, 15]. However, few
studies analyzed the presence and type of inflammatory
cells (i.e. acute vs. chronic) within the prostate by race.
To test this, we investigated the relationship between
71395
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Table 2: Association between Baseline Acute Inflammation and Race
Univariable
Patient Race
No. (%)
OR (95% CI)
P-Value
White
7271 (92.0)
Ref.
Ref.
Black
180 (2.3)
0.85 (0.55, 1.31)
0.467
Asian
Hispanic

131 (1.7)
319 (4.0)

1.94 (1.31, 2.88)
0.91 (0.66, 1.25)

0.001
0.560

Multivariable*
OR (95% CI)
Ref.
0.65 (0.41, 1.03)

P-value
Ref.
0.065

1.74 (1.14, 2.65)
1.04 (0.73, 1.49)

0.010
0.826

Abbreviations: 95% CI, 95% confidence interval; OR odds ratio.
*Adjusted for baseline age, race, region, DRE (digital rectal examination), prostate volume, PSA (prostate-specific antigen),
smoking, aspirin/NSAID use, and biopsy results.
Table 3: Association between Baseline Chronic Inflammation and Race
Univariable
Multivariable*
Patient Race
No. (%)
OR (95% CI)
P-Value
OR (95% CI)
White
7271 (92.0)
Ref.
Ref.
Ref.
Black
180 (2.3)
1.36 (0.93, 2.01)
0.116
1.11 (0.74, 1.67)
Asian
131 (1.7)
1.19 (0.77, 1.83)
0.431
1.01 (0.65, 1.59)
Hispanic
319 (4.0)
1.27 (0.96, 1.69)
0.099
1.04 (0.76, 1.42)

P-value
Ref.
0.611
0.949
0.822

Abbreviations: 95% CI, 95% confidence interval; OR odds ratio.
*Adjusted for baseline age, race, region, DRE (digital rectal examination), prostate volume, PSA (prostate-specific antigen),
smoking, aspirin/NSAID use, and biopsy results.
prostate inflammation, both chronic and acute, and race in
REDUCE, where all men had a negative pre-study biopsy
and wherein we previously showed inflammation was
related to lower future PC risk [2]. As we hypothesized,
compared to white men, black men were less likely and
Asian men more likely to have acute prostate inflammation
in their negative biopsies, though associations for black
men were not statistically significant. No associations were
found between chronic prostate inflammation and race.
These findings suggest racial differences in acute prostate
inflammation may explain, in part, racial differences in PC
risk, especially among Asian men.
Few studies to date analyzed prostate inflammation
as a function of race. A small study (n = 210 of which
49 were black) analyzed radical prostatectomy tissue and
reported black men had similar rates of inflammation
as white men [10]. However, results were not stratified
by acute vs. chronic inflammation. Given chronic
inflammation is more common than acute, these results
were most likely driven by chronic inflammation. A recent
prostate cancer case-control study (n = 345 white, n = 229
black men) examined glandular and stromal inflammation
by race [16]. Consistent with the prior study, they found
no overall difference in rates of histological inflammation.
However, black men had 32% lower rates of glandular
inflammation. Whether glandular inflammation is the
same as acute inflammation is not exactly clear as one is
defined by cellular compartment (i.e. glandular) whereas
acute is defined by the type of cells present. Nonetheless,
this study did suggest some racial differences in prostatic
inflammation levels. Another small study by Zlotta et
al. (n = 320 of which 100 were Asian) analyzed prostate
www.impactjournals.com/oncotarget

inflammation on autopsies of Asian and Caucasian
men with no known history of PC [17] and also found
no differences in inflammation by race. In this study,
the authors examined acute and chronic inflammation
separately and found no association with either type of
inflammation. Our results are in-part in line with these
data. Specifically, we also found that on negative prestudy prostate biopsies, there were no differences in
chronic inflammation by race. However, we found acute
prostate inflammation was more prevalent in Asians and
suggestively less prevalent in black men compared to
white men. Thus, while all 3 studies agree on the lack
of association between race and chronic inflammation,
there is disagreement on acute inflammation. In part this
may stem from statistical power. Acute inflammation was
present in only 15% of biopsies in our study (12% in the
Zlotta et al paper). Thus, with few events, it may be tough
to detect associations in a study with a few hundred men.
However, as our study included 7,982 men of which 131
were Asian, we had increased power to observe differences
in an uncommon event such as acute inflammation
between races. However, despite being a slightly larger
study, our overall numbers of non-white men was limited.
As such, whether the limited number of black men affected
our ability to detect a significant association between
acute inflammation with black race or whether this truly
reflects no association requires further study. Alternatively,
study population differences may account for the different
results. Our study included a more homogenous group all with an elevated PSA and a negative prostate biopsy
who were healthy enough to enroll on a phase III PC
prevention study. The Zlotta et al, study included men
71396
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MATERIALS AND METHODS

who died including a large percentage who died of cancers
(other than prostate) - 56% of the Asian men. Finally, there
were differences in statistical approaches. The Zlotta et
al, study did not perform multivariable analysis despite
clear differences between Asians and Caucasians - 6 year
difference in age, a 20% difference in prostate size, and
a big difference in history of non-PC (59% in the Asians
vs. 12% in Caucasians). Whether adjusting for these
differences would have affected the results is unknown.
While the role of inflammation in prostate tissue
is controversial, our previous data from the same dataset
showed both acute and chronic inflammation in prestudy negative biopsy was associated with reduced PC
risk in repeat 2-yr biopsies [2]. However, only acute
inflammation predicted lower PC risk at the 4-yr biopsy.
Given differences in inflammation by race were only in
acute inflammation, this raises the hypothesis that racial
differences in inflammation may in part be responsible
for PC racial disparities. If our results are validated in
future studies, additional work is needed to determine
whether inflammatory cell infiltrate difference results
from host differences in genetics, lifestyle, or prostate
microenvironment [18]. Perhaps more interestingly, the
suggestion that acute inflammation may be protective
against the future development of PC is intriguing and
requires further follow up. In lung cancer, neutrophilic
infiltration (acute inflammation) has recently been shown
to include both N1 (protective) and N2 (pro-carcinogenic)
phenotypes [19]. Follow-up studies designed to
comprehensively profile the phenotypic characteristics of
prostatic acute inflammation are under way.
Our study had key strengths: large samples of white
subjects, centrally and systematically read pathology, and
data available on key confounding variables including
PSA, prostate size, smoking, and aspirin and/or NSAID
use. However, though our study was larger than prior
studies, the number of black and Asian men was modest
and only slightly larger than prior studies. While we
defined inflammation as obtained from central pathology
as acute or chronic, a more detailed analysis of the exact
cells that exist within the prostate may yield greater
insight into the association between race, inflammation,
and PC biology. As noted, a key strength of this study is
that inflammation was systematically graded by a single
pathologist and the uniform enrollment criteria.

Study population
REDUCE was a 4-year, multicenter, randomized,
double-blind, placebo-controlled study. While study
details are described elsewhere, they are not relevant
to this analysis in that we only used baseline data [6,
20]. Eligibility requirements were age 50-75 years old,
serum PSA 2.5-10.0 ng/ml if 50-60 years or 3.0-10.0 ng/
ml if > 60 years, and a single, negative prostate biopsy
(6-12 cores) within 6 months prior of enrollment and
independent of the study. Men with past history of PC,
prostate surgery, prostate volume > 80 ml, or IPSS > 25 or
> 20 on alpha-blockers were excluded. Of 8,122 subjects
in the efficacy population, we excluded men with missing
baseline data on race (n = 1), PSA (n = 18), DRE (n = 15),
prostate volume (n = 100), or smoking status (n = 6). A
total of 7,982 subjects met the inclusion criteria.
Each core was centrally read by a single pathologist
and coded as present or absent for acute and chronic
prostate inflammation. A patient was considered to have
inflammation if any core was positive for inflammation.
Chronic inflammation consisted mainly of lymphocytes
and a variable number of plasma cells and macrophages.
Acute inflammation consisted of a neutrophilic infiltrate
[2]. Thus, as acute and chronic inflammation are not
mutually exclusive, a patient could have no inflammation,
acute only, chronic only, or both. As the pathophysiology
of acute and chronic inflammation likely differ, they
were analyzed as separate and independent conditions.
Race was self-reported as “black”, “white”, “Hispanic”,
“Asian”, or “other”.

Statistical analysis
The association between baseline acute and chronic
inflammation and baseline clinical characteristics was
examined using student t-test, Wilcoxon rank-sum or χ² for
continuous normal, continuous non-normal and categorical
variables, respectively. Logistic regression was used to test
the association between race (primary predictor variable)
and presence or absence of baseline acute and chronic
inflammation (primary outcome variables). Multivariable
analyses were adjusted for baseline age (continuous),
PSA (continuous), DRE (abnormal vs. normal), smoking
status (non-smoker, former, current), aspirin and/or
NSAID use (yes vs. no), and geographic region (North
America, Europe, other). As all men in this study had
an elevated PSA and given that inflammation as well
as prostate cancer and prostatic enlargement are known
causes of an elevated PSA, we further adjusted for prostate
volume (continuous), and a 4-tiered categorical variable
of whether over the course of the 4-year REDUCE study,

CONCLUSIONS
We found that in men with negative prostate
biopsies and an elevated PSA, black men had suggestively
less acute inflammation while Asian men had significantly
more acute inflammation with no race differences in
chronic inflammation. If confirmed in future studies, these
results suggest racial differences in prostatic inflammation,
especially in Asian men, may in part be involved in
explaining racial differences in PC risk.
www.impactjournals.com/oncotarget
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the subjects had 1 negative prostate biopsy vs. 2+ negative
biopsies vs. no on-study biopsy, or found to have prostate
cancer on follow-up biopsy. Sensitivity analyses were
conducted excluding men from Europe, as there were few
black and Asian men (race/ethnicity was self-reported).
We also conducted a subgroup analysis among NSAID
and/or aspirin users and non-users. Also, we examined the
effect of not adjusting for future prostate cancer diagnosis
given this information was not available at the time of
baseline. Statistical significance was defined as p < 0.05.
All analysis was performed using Stata v13.1.
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